Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02632409 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02632409 · ClinicalTrials.gov record · last posted 2026-07-30

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

Name: An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer — clinical trial record (NCT02632409)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CheckMate 274

StatusCompleted

PhasePhase 3

SponsorBristol-Myers Squibb

Started2016-03-22

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.

Protocol amendment history 2 changes detected by DataLookout

2026-07-31

Trial completed

2026-07-31

Completion moved earlier: 2027-05-27 → 2026-05-19

Trial Details

NCT Number	NCT02632409
Lead Sponsor	Bristol-Myers Squibb Collaborators: Ono Pharmaceutical Co., Ltd.
Conditions	Various Advanced Cancer
Enrollment	709 participants
Start Date	2016-03-22
Primary Completion	2020-07-17 (estimated)
Study Completion	2026-05-19 (estimated)
Updated on ClinicalTrials.gov	2026-07-30